Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

i3 Health

Current Trends in the Management of Castration-Resistant Prostate Cancer

Access Activity

Overview / Abstract:


Prostate cancer is the most common tumor type in men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 29,430 deaths annually. Median overall survival remains less than 2 years.


Medical oncologists, urologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of patients with CRPC.


Upon completion of this activity, participants should be able to:

1. Assess predictive and prognostic markers to refine treatment planning for individual patients with CRPC
2. Distinguish findings from recent clinical studies on novel combination and sequential treatment strategies for nonmetastatic and metastatic CRPC
3. Develop supportive care plans to monitor and manage adverse events associated with novel treatment strategies for CRPC


Jan 14, 2020


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Monograph, Online

Credits / Hours




Presenters / Authors / Faculty

Alicia K. Morgans, MD, MPH (Chairperson)
Associate Professor of Medicine
Northwestern University Feinberg School of Medicine

Tanya Dorff, MD
Associate Clinical Professor
City of Hope

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Sanofi Genzyme.

Keywords / Search Terms

i3 Health i3 Health, CRPC, prostate cancer, castration-resistant prostate cancer, urology, oncology, CME, CE, free CE, free CME, ILNA points Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.